---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-084902"
form_type: "8-K/A"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2024-04-02T23:59:59+00:00"
generated_at: "2026-06-04T03:41:43.185980+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Therapeutics discloses CFO Lees-Rolfe's compensation: $345K salary, 90K option

## Summary
- Base salary of $345,000 per annum with discretionary annual target bonus of 30% of base.
- Initial stock option for 90,000 shares at $2.16, vesting in three equal annual installments.
- Non-CIC termination severance: 9 months base salary plus COBRA reimbursement for 9 months.
- CIC termination (within 12 months post-change): 12 months base salary lump sum, full equity vesting, one-time Target Bonus.
- Employment Agreement effective April 1, 2024; role as Chief Financial Officer.

## SEC filing metadata
- accession: 0001193125-24-084902
- form_type: 8-K/A
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2024-04-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312524084902/0001193125-24-084902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312524084902/d821381d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-084902
- JSON: https://secwatch.observer/filing/0001193125-24-084902.json
- Plain text: https://secwatch.observer/filing/0001193125-24-084902.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.